Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Recurso digital |
| Idioma: | |
| Publicado: |
Zenodo
2026
|
| Subjects: | |
| Acceso en liña: | https://doi.org/10.5281/zenodo.20133634 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Table of Contents:
- <p class="MsoNormal"><span>One of the most common neuropsychiatric disorders in the world is anxiety disorders, which are complex in nature due to a complex interaction of neurochemical, inflammatory, and environmental factors. The emerging evidence reveals the central role of the gut-brain axis in regulating emotional and behavioral responses by a two-way communication between the gastrointestinal tract and the central nervous system. The dysregulation of gut microbiota has been strongly linked to the increased oxidative stress, neuroinflammation, and neurotransmitter imbalance, which are all associated with the pathogenesis of anxiety disorders.Plant-derived polyphenols have garnered much attention in recent years due to their multifunctional biological properties, including antioxidant, anti-inflammatory, and neuroprotective effects. These bioactive compounds have the potential to mediate the composition of gut microbiota, improve the integrity of the intestinal barrier, and regulate the metabolites produced by microbes, such as short-chain fatty acids, thereby affecting brain function and behavior. Moreover, polyphenols are also known to interact with the major neurotransmitter systems, such as serotonergic and GABAergic systems, which also contributes to their anxiolytic potential.The purpose of this review is to present extensive mechanistic evidence of how plant-derived polyphenols can be used to target the gut-brain axis in anxiety disorders. It also points out the existing preclinical evidence, existing research gaps, and future therapeutic prospects of developing novel, safer, and more effective anxiolytic strategies.</span></p>